( ) -q-27- UNDATED (Correspondent Jeremy House) “of overseas travel.” U.S. health inspectors are still struggling to address a massive backlog of pharmaceutical plants that went uninspected during disruptions caused by COVID-19. [CutID: <Cuts> PHARMACEUTICAL-PLANTS-house-q-FRIam.mp3 Time: 27s Title: PHARMACEUTICAL-PLANTS-house-q-FRIam Out-cue: of overseas travel] TAG: Correspondent Jeremy House reporting. —————————– VERBATIM: According to an analysis of […]
Audio
Health officials forced to deal with uninspected pharmaceutical plants
( ) -q-27- UNDATED (Correspondent Jeremy House) “of overseas travel.”
U.S. health inspectors are still struggling to address a massive backlog of pharmaceutical plants that went uninspected during disruptions caused by COVID-19.
[CutID: <Cuts> PHARMACEUTICAL-PLANTS-house-q-FRIam.mp3
Time: 27s
Title: PHARMACEUTICAL-PLANTS-house-q-FRIam
Out-cue: of overseas travel]
TAG: Correspondent Jeremy House reporting.
—————————–
VERBATIM: According to an analysis of government data by the Associated Press, roughly 2,000 drug manufacturing sites around the world have not had a Food and Drug Administration inspection for quality since before the pandemic. The FDA considers plants that have gone more than five years without an inspection to be a significant risk. Agency officials say their work has been hampered by difficulties recruiting and retaining inspectors, who face a grueling schedule of overseas travel.